Distribution Channel Leverage McKesson and HubSpot-enabled marketing to target hospital networks, oncology centers, and settings requiring ready-to-use injectable meds. Expand with additional wholesalers and direct hospital contracts; use account-based marketing to engage procurement and clinical leaders.

Portfolio Growth The ongoing launches across Cyclophosphamide, Methylene Blue, Tranexamic Acid, Baclofen injections indicate a growing specialty injectable portfolio. Cross-sell into cancer treatment centers, operating rooms, and neurology clinics; offer bundled procurement options and lifecycle management services.

Market Demand Rising demand for ready-to-dilute and multi-dose injectable medicines in hospital settings creates a need for reliable supply chains. Nexus's FDA-approved, high-quality manufacturing supports long-term hospital contracts and formulary placements in the US.

IP Collaboration Facing patent litigation around cyclophosphamide formulations presents both risk and collaboration opportunities. Explore licensing, cross-licensing, or co-development deals to secure supply and expand product access for customers while mitigating IP risk.

Quality Capacity Award-winning facility status signals scalable, compliant manufacturing and quality assurance. Position Nexus as a CDMO partner for larger pharma or hospital systems seeking dependable injectable manufacturing capacity, fill-finish services, and regulatory support.